Table 3.

Summary of AEs (All Subjects)

	Prefilled Syringe‐Abdomen(n = 20)	Autoinjector‐Abdomen(n = 20)	Prefilled Syringe‐Thigh(n = 20)	Autoinjector‐Thigh(n = 21)	Total (n = 81)
Any a AE, n (%)	5 (25)	12 (60)	13 (65)	11 (52)	41 (51)
Headache	2 (10)	3 (15)	5 (25)	0	10 (12)
Upper respiratory tract infection	0	1 (5)	3 (15)	1 (5)	5 (6)
Viral upper respiratory tract infection	2 (10)	1 (5)	1 (5)	1 (5)	5 (6)
Pruritis	0	1 (5)	2 (10)	1 (5)	4 (5)
Abdominal pain	0	0	0	2 (10)	2 (2)
Gastroenteritis	0	2 (10)	0	0	2 (2)
Injection‐site pruritus	0	0	2 (10)	0	2 (2)
Drug‐related b AE, n (%)	0	0	5 (25)	4 (19)	9 (11)
Injection‐site erythema	0	0	1 (5)	1 (5)	2 (2)
Injection‐site pruritus	0	0	2 (10)	0	2 (2)
Nausea	0	0	1 (5)	1 (5)	2 (2)
Abdominal pain	0	0	0	1 (5)	1 (1)
Contusion	0	0	0	1 (5)	1 (1)
Decreased appetite	0	0	1 (5)	0	1 (1)
Injection‐site urticaria	0	0	1 (5)	0	1 (1)
Nasal congestion	0	0	1 (5)	0	1 (1)
Urticaria	0	0	1 (5)	0	1 (1)

AE, adverse event.

^aAEs occurring in ≥10% of subjects in any study group are listed.

^bAll related AEs are listed.